NeuroSense Therapeutics (NRSN) vs Scienture (SCNX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
NeuroSense Therapeutics is the larger company by market cap ($7.2 million vs $6.2 million), about 1.2 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | NRSN | SCNX |
|---|---|---|
| Share price | $3.80 | $3.76 |
| Market cap | $7.21M | $6.18M |
| 1-day change | +1.60% | -2.59% |
| EPS (TTM) | $-47.10 | $-52.75 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $26.64 | $65.00 |
| 52-week low | $3.56 | $3.23 |
| Distance from 52-week high | -85.74% | -94.22% |
| Analyst consensus | strong_buy | buy |
| Avg. price target upside | +2461.32% | +897.34% |
| Average volume | 21.29K | 212.16K |
| Shares outstanding | 1.90M | 1.64M |
| Employees | 17 | 4 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About NeuroSense Therapeutics
NRSN stock →NeuroSense Therapeutics Ltd., a clinical-stage biotechnology company, focuses on discovering and developing treatments for patients suffering from neurodegenerative diseases in the United States and internationally. The company's lead product is PrimeC, an extended-release oral formulation of a fixed-dose combination of ciprofloxacin and celecoxib, currently under Phase 2b/3 clinical trials for the treatment of amyotrophic lateral sclerosis, and completed Phase 2 clinical trials for the treatment of Alzheimer's, as well as under preclinical studies for the treatment of Parkinson's disease.
Health Care · Biotechnology: Pharmaceutical Preparations · 17 employees
About Scienture
SCNX stock →Scienture Holdings, Inc. operates as pharmaceutical company that focuses on development and commercialization of products for the treatment of central nervous system and cardiovascular diseases in the United States.
Health Care · Biotechnology: Pharmaceutical Preparations · 4 employees
NRSN vs SCNX FAQ
Which is bigger, NeuroSense Therapeutics or Scienture?
NeuroSense Therapeutics (NRSN) is larger, with a market capitalization of $7.21M compared with $6.18M for Scienture (SCNX).
Are NeuroSense Therapeutics and Scienture in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.